Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Interested in exploring peptide therapy
The 2013 Endocrinology paper used a GHRH-receptor-targeted botulinum-neurotoxin construct to characterise pulsatile GH secretion mechanisms (PMID 23825127)
Research-grade specs Components: GHK-Cu + BPC-157 + TB-500 Total strength: 70 mg per vial Format: Lyophilized powder, single-vial blend CAS Number: N/A (blend) Pathways studied: Matrix remodelling (GHK-Cu), cell migration and signalling (BPC-157, TB-500) Studied applications Multi-pathway combination research Comparative single-compound vs combination studies Copper-peptide and tripeptide comparative research Cytoskeletal and matrix pathway interaction research Quality & trust 99% HPLC purity, third-party tested Mass spectrometry identity confirmation LAL endotoxin testing on every batch Batch-specific Certificate of Analysis included cGMP manufactured in Dallas, Texas (USA) USA same-day shipping (orders before 2pm CT M-F) Free domestic shipping on orders over $200 Storage & handling Store lyophilized vials refrigerated at 28C, protected from light and heat Reconstitute with bacteriostatic water
TB-500 nasal spray dosing Injectable TB-500 typically follows a loading and maintenance pattern
AOD-9604 Before and After: Realistic Timeline by Week Based on the available clinical data, the mechanism of action, and the pharmacokinetics of subcutaneous administration, here is a realistic timeline of what AOD-9604 users may experience
US$ 25.40
US$ 27.54
US$ 24.73
US$ 26.60
US$ 25.01
US$ 20.72
US$ 26.16
US$ 29.56
US$ 21.48
US$ 24.95
US$ 27.94
US$ 26.67
US$ 29.83
US$ 23.29
